.png)
Enlivex
Allocetra immunotherapy now for KNEE OSTEOARTHRITIS/longevity + crypto treasury (Rain Protocol) — sepsis focus dropped; EXCLUDE-recommended
Latest event found: 22 Sep 2026 · 28 days ago
Vitality Radar
Pillar Analysis
Strategic Assessment
Strategic Vector
Enlivex is shifting from a sepsis-focused macrophage cell-therapy strategy toward a broader longevity platform, with Allocetra advancing into a global Phase 2b osteoarthritis program. The 2026 financing activity indicates aggressive capital expansion, but the terminated RAIN-token financing introduces execution and financing-structure risk.
Efficiency Ratio
A lean 11-50-person organization is advancing a multi-country clinical pipeline, suggesting high resource-to-output efficiency but limited visible organizational depth for late-stage development and commercialization.
Evidence Signals
1 negative signalEnlivex announced termination of the previously announced securities purchase agreement with the Rain Foundation involving financing payable in RAIN tokens.
Enlivex announced a securities purchase agreement for a private placement of 80,000,000 ordinary shares at $5 per share, representing gross proceeds of $400,000,000, with an additional option for up to $400,000,000.
Enlivex commenced its global Phase 2b knee osteoarthritis trial and dosed the first patient.
The Danish Medicines Agency approved Enlivex's Clinical Trial Application for the Phase 2b Allocetra trial in moderate-to-severe age-related symptomatic primary knee osteoarthritis.
The FDA cleared Enlivex's Investigational New Drug application for Allocetra in moderate-to-severe age-related symptomatic primary knee osteoarthritis, enabling initiation of a global Phase 2b trial.
Enlivex announced that it raised and closed a $9,500,000 financing transaction.
- About
- Israeli biotech company (Enlivex Ltd.; Nasdaq: ENLV; HQ Nes-Ziona, Israel — 14 Einstein St.; ~11-50 staff). As of 2026 Enlivex brands itself 'The Quality Longevity Company,' combining a clinical biotech platform with a prediction-markets crypto-treasury strategy (Rain Protocol). Its clinical asset Allocetra — an off-the-shelf macrophage-reprogramming immunotherapy — is now in development for aging-related diseases, initially focused on knee osteoarthritis. Its earlier sepsis / organ-failure program — the basis on which Enlivex was mapped as a mass-casualty medical countermeasure (C12-09) — is no longer the company's stated focus. Defense relevance has effectively lapsed: the current focus (knee OA / longevity) is not defense-relevant and the company's other pillar is a crypto prediction-markets treasury. Recommended for EXCLUSION from the defense-health map.
- Tags
- #sepsis #celltherapy #macrophage #allocetra #organfailure #medicalcountermeasure #rxbio #dualuse #FLAG-cryptopivot